CADILA HEALTHCARE LTD. - 532321 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
Zydus Cadila's Covid-19 vaccine can be available from first week of Oct
The Union government is expecting Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D to be available from the first week of October. Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday. Indigenously developed Zydus Cadila's ZyCoV-D on Friday received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in the country which would be administered in the age group of 12-18 years. On the kind of negotiations in terms of pricing and when the government plans to procure ZyCoV-D, Union Health Secretary Rajesh Bhushan said, "Coming to negotiations, what we have understood from media reports as well as our own engagement with the vaccine manufacturing company is that they would be in a position to make available this vaccine from the first week of October." "So we are in talks with them and the moment we crystallise CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate
NTAGI to soon chalk out roadmap to introduce Zydus Cadila's vaccine in Covid inoculation drive
The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received Emergency Use Authorisation from the drug regulator on August 20 making it the first vaccine to be administered in the age group of 12-18 years in the country
Buy Cadila Healthcare target of Rs 695: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 695 in its research report dated dated August 24, 2021. Booster dose: Cadila share doubles in 18 months
Since vaccine development to EUA , Zydus Cadila stock surges 111%
Conference Call with Cadila Healthcare: Emergency Use Approval of Covid Vaccine
Conference Call with Cadila Healthcare Management and Analysts on Emergency Approval (EUA) of Zycov-D Vaccine against Coronavirus. Listen to the full transcript. CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Emergency Use Approval (EUA) of ZyCov-D vaccine - Conference call with investors and analysts
Zydus to commercialise Zycov-D next month, scale up production to 1 cr by Oct
Dr Sharvil Patel, managing director, Zydus Cadila said the company has started production in small batches and is stockpiling 2-3 million doses of the vaccine from its new facility set up at Ahmedabad